论文部分内容阅读
本研究对根除幽门螺杆菌（Ｈｐ）的三联疗法进行改良，减少其中阿莫西林及甲硝唑的剂量，对Ｈｐ阳性的１７３例慢性胃炎患者及２６７例十二指肠溃疡患者进行Ｈｐ根除治疗。用药方法为胶体次枸橼酸铋（德诺，ＣＢＳ）１２０ｍｇ，阿莫西林２５０ｍｇ，及甲硝唑２００ｍｇ同服，每日４次，连服１４天，Ｈｐ根除率为８６．８％。此外，对４９例慢性胃炎及１０７例十二指肠溃疡Ｈｐ阳性者减少服药次数，采用每日２次给药，连服１４天，Ｈｐ根除率８９．１％。研究证明，低剂量三联疗法Ｈｐ根除率高，不良反应少，有较好的依从性。每日２次服药与每日４次服药临床疗效相似，Ｈｐ根除率差异无显著性（Ｐ＞０．０５）。
In this study, the triple therapy of Helicobacter pylori (Hp) was eradicated to reduce the dose of amoxicillin and metronidazole. Hp eradication was performed on 173 Hp-positive chronic gastritis patients and 267 patients with duodenal ulcer . Drugs for the colloidal bismuth citrate (De Nuo, CBS) 120mg, amoxicillin 250mg, and metronidazole 200mg with the same service, 4 times a day, and even served 14 days, Hp eradication rate was 86.8%. In addition, 49 cases of chronic gastritis and 107 cases of duodenal ulcer Hp-positive patients to reduce the number of medication, the use of twice daily dosing, and even served 14 days, Hp eradication rate of 89.1%. Studies have shown that low-dose triple therapy Hp eradication rate, fewer adverse reactions, better compliance. 2 times daily medication and 4 times daily medication similar clinical efficacy, Hp eradication rate difference was not significant (P> 0.05).